Regulatory

November 27, 2023

Affibody’s Partner ACELYRIN Provides Update on Izokibep Clinical Development Program

Solna, Sweden, November 27, 2023. Affibody’s partner ACELYRIN, INC. (“ACELYRIN”) today provided an update on its izokibep clinical development program, including the ongoing global Phase 2b/3 trial in psoriatic...

Read more

Regulatory

October 3, 2023

Affibody appoints Peter Zerhouni as CFO

Solna, Sweden, October 3, 2023. Affibody AB (“Affibody”) today announced that Peter Zerhouni has been appointed Chief Financial Officer (CFO) of the Company. Peter Zerhouni joined Affibody as Chief...

Read more

Regulatory

September 11, 2023

Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

• The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. • HiSCR75 did meet statistical significance at week 16...

Read more

Regulatory

August 30, 2023

Data demonstrating that Affibody’s PET imaging agent ABY-025 can be used to predict therapeutic response will be presented at EANM

Solna, Sweden, August 30, 2023. Affibody AB (“Affibody”) today announced the presentation of data from patients in a clinical study of the PET imaging agent 68Ga-ABY-025 for non-invasive quantification...

Read more

Regulatory

June 30, 2023

First ten HER2-low patients dosed in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, June 30, 2023. Affibody AB (“Affibody”) today announced that the first ten patients have been dosed in a Phase 2 clinical basket study of the PET imaging...

Read more

Regulatory

April 11, 2023

Positive Long-term Results with Izokibep in Psoriatic Arthritis

• Affibody’s partner ACELYRIN, INC today announced 46 weeks Phase 2 data where izokibep demonstrated high levels of response across psoriatic arthritis disease manifestations.• Long-term data build on statistically...

Read more

Regulatory

March 30, 2023

Affibody appoints Peter Zerhouni as CBO

· Peter Zerhouni joins as Chief Business Officer on April 3, 2023. Solna, Sweden, March 30, 2023 – Affibody AB (“Affibody”) today announced the appointment of Peter Zerhouni as CBO. He...

Read more

Regulatory

March 18, 2023

Izokibep Phase 2b/3 Hidradenitis Suppurativa Data Presented at the 2023 American Academy of Dermatology Annual Meeting

• At 12 weeks, 57% of patients achieved HiSCR75, 38% achieved HiSCR90 and 33% achieved HiSCR100. • Safety results were consistent with previous trials of izokibep, with no increased...

Read more

Regulatory

March 7, 2023

Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases

Affibody and Chiesi Group will collaborate closely to develop novel Affibody® molecules as innovative treatments for respiratory diseases.  This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with...

Read more